Helus Pharma reports positive Phase 3 results for HLP003 in major depressive disorder
The APPROACH study met its primary and key secondary MADRS endpoints with effects seen by Day 2, the company said on November 16, 2026.
SEC filing
9 stories
The APPROACH study met its primary and key secondary MADRS endpoints with effects seen by Day 2, the company said on November 16, 2026.
SEC filing
The company reported fiscal second-quarter results with its pivotal HLP003 depression study fully enrolled and topline data still expected in the fourth quarter of 2026.
SEC filing
Eric So and Paul Glavine exit executive posts as Mark Lawson becomes independent board chair, the company said on October 27, 2026.
SEC filing
The company said its HLP003 Phase 3 data remain on track for Q4 2026, while a new HLP004 Phase 2 monotherapy study for generalized anxiety disorder is expected to start in Q1 2027.
SEC filing
The clinical-stage CNS drug developer moved its longtime scientific adviser onto the board as it pushes HLP003 through Phase 3 and HLP004 through Phase 2.
SEC filing
Michael Halstead will take part in a virtual fireside chat on September 23, 2026 at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit.
SEC filing
CEO Michael Halstead will hold fireside chats at Cantor, H.C. Wainwright, and Morgan Stanley healthcare conferences between September 11 and 16, 2026.
SEC filing (3)
The filing covers options set to vest over eight quarterly installments starting August 19, 2026, with a total potential offering value of $261,987.
SEC filing